Oral OTEZLA(R) (apremilast) long-term safety data reported in psoriasis
Celgene announced that long-term safety findings from ongoing clinical trials of apremilast, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic AMP. As previously announced, RADIANCE met its primary efficacy endpoint. September 28, 2016